Join Growin Stock Community!

Bioceres crop solutions corp.BIOX.US Overview

US StockBasic Materials
(No presentation for BIOX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BIOX AI Insights

BIOX Overall Performance

BIOX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BIOX Recent Performance

-3.82%

Bioceres crop solutions corp.

-0.69%

Avg of Sector

-0.31%

S&P500

BIOX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BIOX Key Information

BIOX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BIOX Profile

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. The company also offers HB4, a drought tolerant seed technology program. It operates in Argentina, Uruguay, France, South Africa, and internationally. The company was founded in 2001 and is headquartered in Rosario, Argentina. Bioceres Crop Solutions Corp. is a subsidiary of Bioceres LLC.

Price of BIOX

BIOX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BIOX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.89
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.11
PB Ratio
0.14
Price-to-FCF
0.74
METRIC
VALUE
vs. INDUSTRY
Gross Margin
40.40%
Net Margin
-17.79%
Revenue Growth (YoY)
-28.14%
Profit Growth (YoY)
-28.34%
3-Year Revenue Growth
-15.29%
3-Year Profit Growth
-11.24%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.89
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.11
PB Ratio
0.14
Price-to-FCF
0.74
Gross Margin
40.40%
Net Margin
-17.79%
Revenue Growth (YoY)
-28.14%
Profit Growth (YoY)
-28.34%
3-Year Revenue Growth
-15.29%
3-Year Profit Growth
-11.24%

  • When is BIOX's latest earnings report released?

    The most recent financial report for Bioceres crop solutions corp. (BIOX) covers the period of 2026Q1 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BIOX's short-term business performance and financial health. For the latest updates on BIOX's earnings releases, visit this page regularly.

  • What is the operating profit of BIOX?

    According to the latest financial report, Bioceres crop solutions corp. (BIOX) reported an Operating Profit of 6.91M with an Operating Margin of 8.95% this period, representing a growth of 133.87% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BIOX's revenue growth?

    In the latest financial report, Bioceres crop solutions corp. (BIOX) announced revenue of 77.26M, with a Year-Over-Year growth rate of -17.68%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BIOX have?

    As of the end of the reporting period, Bioceres crop solutions corp. (BIOX) had total debt of 258.45M, with a debt ratio of 0.35. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BIOX have?

    At the end of the period, Bioceres crop solutions corp. (BIOX) held Total Cash and Cash Equivalents of 15.51M, accounting for 0.02 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BIOX go with three margins increasing?

    In the latest report, Bioceres crop solutions corp. (BIOX) did not achieve the “three margins increasing” benchmark, with a gross margin of 46.5%%, operating margin of 8.95%%, and net margin of -9.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BIOX's profit trajectory and future growth potential.

  • Is BIOX's EPS continuing to grow?

    According to the past four quarterly reports, Bioceres crop solutions corp. (BIOX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.12. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BIOX?

    Bioceres crop solutions corp. (BIOX)'s Free Cash Flow (FCF) for the period is 13.04M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 409% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.